Moderna, Inc. highlighted several developments on 27 March to show the progress the company is making on expanding its mRNA-based vaccine business, with positive Phase III data for its next-generation COVID-19 vaccine candidate, a May US action date for its respiratory syncytial virus (RSV) vaccine mRNA-1345, ongoing Phase III development of a combination respiratory vaccine for COVID-19 and influenza and up to $750m from Blackstone Life Sciences to fund its overall flu vaccine program.
Key Takeaways
-
Moderna reported Phase III data on 26 March demonstrating stronger immune response than Spikevax against the original and Omicron variants of COVID-19.
-
Blackstone Life Sciences is providing up to $750m in funding for Moderna’s flu vaccine efforts, in exchange for milestone and royalty rights
A day earlier, the company reported that mRNA-1283, its next-generation COVID-19 vaccine candidate, which incorporates a shorter mRNA that may yield higher immune response at lower doses, demonstrated a more robust immune response against two variants of the virus in a head-to-head Phase III trial against Spikevax (mRNA-1273.222), its currently approved vaccine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
